This company seems to have been delisted
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Clovis Oncology
CLVS
NZ$0.14
Share price
0.00%
Change (1 day)
-95.13%
Change (1 year)
Categories
Clovis Oncology (CLVS) Fails to deliver data
Key failure to deliver metrics for Clovis Oncology:
- Last SEC data release: 2022-12-14
- Last 15 days FTD volume: NZ$0.12 M
- Last 3 months FTD volume: NZ$7.84 M
- Last year FTD volume: NZ$7.84 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Clovis Oncology (CLVS) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Clovis Oncology (CLVS) - since 2013
Volume in USD (price x number of shares), data since 2013Clovis Oncology (CLVS) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2022 | NZ$0.10 B | 55.95% |
| 2021 | NZ$64.22 M | -74.65% |
| 2020 | NZ$0.25 B | -49.12% |
| 2019 | NZ$0.49 B | 1053.83% |
| 2018 | NZ$43.14 M | 68.49% |
| 2017 | NZ$25.6 M | -50.75% |
| 2016 | NZ$51.99 M | 5.81% |
| 2015 | NZ$49.14 M | -8.09% |
| 2014 | NZ$53.46 M | 1150.43% |
| 2013 | NZ$4.27 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | NZ$3.61 M | NZ$21.45 M | 🇺🇸 USA |
 AstraZeneca AZN | NZ$23.77 M | NZ$0.14 B | 🇬🇧 UK |
 Pfizer PFE | NZ$26.37 M | NZ$0.27 B | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$10.58 M | NZ$0.12 B | 🇺🇸 USA |
 AbbVie ABBV | NZ$25.73 M | NZ$0.20 B | 🇺🇸 USA |
 Eli Lilly LLY | NZ$37.29 M | NZ$0.20 B | 🇺🇸 USA |